![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Recommends Primary Endpoints, Assessment Tools for Ulcerative Colitis Therapies
FDA Recommends Primary Endpoints, Assessment Tools for Ulcerative Colitis Therapies
![](https://www.fdanews.com/ext/resources/test/Device_Images4/FDA_Logo_Large.gif?t=1486528488&width=430)
August 11, 2016
The FDA wants drugmakers to use clinical remission as their primary endpoint when conducting trials for short-term ulcerative colitis therapies.
The agency is relegating other data points in ulcerative colitis cases — such as stool frequency, rectal bleeding and endoscopy subscore — to secondary endpoints in a draft guidance. The document focuses exclusively on efficacy endpoints and suggests both ideal and practical assessment tools.
To evaluate these endpoints, the FDA said patient-reported outcomes, observer-reported outcomes and clinician-reported outcomes represent “the three clinical outcome assessment types relevant to the measurement” of ulcerative colitis signs and symptoms.
Upcoming Events
-
21Oct